Stockscreener 앱 받기
0.9336
0.27%
0.0025
Iterum Therapeutics Plc 주식(ITRM)의 최신 뉴스
Pfizer grants Iterum payment extension for FDA-approved antibiotic By Investing.com - Investing.com South Africa
Pfizer grants Iterum payment extension for FDA-approved antibiotic - Investing.com Australia
Iterum Therapeutics (ITRM) Extends $20M Payment Deadline with Pf - GuruFocus
Iterum Therapeutics Announces Extension of Term of Promissory No - GuruFocus
Iterum Therapeutics Announces Extension of Term of Promissory Note - The Manila Times
Iterum Therapeutics Announces Extension of $20 Million Regulatory Milestone Payment Deadline with Pfizer to 2029 - Nasdaq
Iterum Gains 3-Year Extension on $20M Pfizer Payment, Strengthens ORLYNVAH Launch Strategy - Stock Titan
Iterum targets ORLYNVAH US launch by Q4 2025 while extending cash runway into 2026 - MSN
When Will Iterum Therapeutics plc (NASDAQ:ITRM) Become Profitable? - simplywall.st
Iterum Therapeutics plc (NASDAQ:ITRM) Q1 2025 Earnings Call Transcript - Insider Monkey
Iterum Therapeutics PLC (ITRM) Q1 2025 Earnings Call Highlights: Strategic Moves and Financial ... - Yahoo Finance
Iterum Therapeutics PLC (ITRM) Q1 2025 Earnings Call Highlights: - GuruFocus
ITRM Plans Fourth-Quarter Launch for ORLYNVAH in UTI Treatment | - GuruFocus
Iterum Therapeutics (ITRM) Projects Adequate Funding Until 2026 - GuruFocus
Iterum Therapeutics plc SEC 10-Q Report - TradingView
Iterum Therapeutics Reports First Quarter 2025 Financial Results - The Manila Times
Transcript : Iterum Therapeutics plc, Q1 2025 Earnings Call, May 13, 2025 - marketscreener.com
Q1 Earnings Estimate for ITRM Issued By HC Wainwright - Defense World
Iterum Therapeutics’ (ITRM) Buy Rating Reiterated at HC Wainwright - Defense World
Iterum Therapeutics plc (NASDAQ:ITRM): When Will It Breakeven? - Yahoo Finance
Iterum Therapeutics (ITRM) to Release Quarterly Earnings on Monday - Defense World
Iterum Therapeutics (ITRM) Receives Buy Rating from HC Wainwrigh - GuruFocus
Iterum Therapeutics (ITRM) Receives Buy Rating from Analyst | IT - GuruFocus
Iterum Therapeutics to Report First Quarter 2025 Financial Results on May 13, 2025 - Yahoo Finance
Renaissance Technologies LLC Purchases Shares of 438,816 Iterum Therapeutics plc (NASDAQ:ITRM) - Defense World
Check Out Iterum Therapeutics Plc (ITRM)’s Trade Data Rather Than the Analysts’ Views - Sete News
Iterum Therapeutics Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares - The Manila Times
Iterum Therapeutics Raises $5M from Single Investor: Major Push for Antibiotic Commercialization - Stock Titan
Iterum Therapeutics Plc: Rising -64.90% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com
Iterum Therapeutics Plc (ITRM) Becoming More Attractive for Investors - knoxdaily.com
Iterum Therapeutics (ITRM) Secures $5 Million in Direct Offering - GuruFocus
Evaluating ITRM’s financial ratios for a profitable investment - uspostnews.com
Iterum Therapeutics secures $5 million in direct offering - Investing.com
Iterum Therapeutics Announces $5 Million Registered Direct Offering Of Ordinary Shares - marketscreener.com
Iterum Therapeutics plc Announces Definitive Agreement for $5 Million Registered Direct Offering of Shares - Nasdaq
Iterum Therapeutics Secures Critical $5M Funding: ORLYNVAH Drug Launch Plans Accelerate - Stock Titan
ITRM’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
Iterum Therapeutics Plc (NASDAQ:ITRM) Shares Surged 24.11% In A Week – But Can It Maintain Its Gains? - Marketing Sentinel
Iterum Therapeutics Presented a Scientific Poster at ECCMID 2025 Highlighting the Impact of Age on Antibiotic Resistance and Efficacy of Antibiotics - The Manila Times
Groundbreaking Research Reveals Age-Specific Patterns in Antibiotic Resistance for UTI Patients - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
What is Iterum Therapeutics Plc (ITRM) Stock Return on Shareholders’ Capital? - Sete News
Iterum Therapeutics Plc (ITRM): Significant Improvements, Worth Considering - stocksregister.com
Sulopenem Etzadroxil/Probenecid (orlynvah) by Iterum - openPR.com
Iterum outlines ORLYNVAH's market potential with exclusivity through 2034 - MSN
Iterum Therapeutics appoints Joseph Whalen to its Board By Investing.com - Investing.com Canada
Iterum Therapeutics appoints Joseph Whalen to its Board - Investing.com
Iterum Therapeutics Appoints New Board Members - TipRanks
Sanctuary Advisors LLC Invests $35,000 in Iterum Therapeutics plc (NASDAQ:ITRM) - Defense World
Iterum Therapeutics plc (NASDAQ:ITRM) Short Interest Down 5.3% in January - Defense World
17.27%
자본화:
|
볼륨(24시간):